---
title: "Xiangxue Pharmaceutical Co., Ltd. (300147.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300147.SZ.md"
symbol: "300147.SZ"
name: "Xiangxue Pharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-21T13:37:47.587Z"
locales:
  - [en](https://longbridge.com/en/quote/300147.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300147.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300147.SZ.md)
---

# Xiangxue Pharmaceutical Co., Ltd. (300147.SZ)

## Company Overview

Xiangxue Pharmaceutical Co.,Ltd. engages in the research and development, production, and sales of modern Chinese medicine in China. The company provides ban lan gen granules, flu-over liquid, juhong cough-off liquid, and juhong cough-off decoction; chinese herbal, such as huazhou citri grandis, goji berry, chrysanthemum, and rose dried buds; beverages, including king sarsae, asia sarsae, diet sarsae, juice soda, soymilk, coconut juice, and fruit enzyme; and antiviral oral liquids under the Xiangxue brand name. It also provides medical devices, which includes disposable stereoscopic fixation system for brain; medical orthopedic and cosmetic adhesives; medical tumor serosa sealing adhesives; medical anastomotic adhesives; medical aural and encephalic adhesives; medical obturation adhesives; medical adhesives; and endoscopic trocar.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.xphcn.com](https://www.xphcn.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: E
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: E (0.83)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 213 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: E

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -10.65% |  |
| Net Profit YoY | -55.48% |  |
| P/B Ratio | -14.31 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6732079584.61 |  |
| Revenue | 1525624835.40 |  |

#### Multi Score Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.00% | D |
| Profit Margin | 0.00% | D |
| Gross Margin | 35.48% | C |
| Revenue YoY | -10.65% | E |
| Net Profit YoY | -55.48% | D |
| Total Assets YoY | -10.48% | E |
| Net Assets YoY | -106.19% | E |
| Cash Flow Margin | -11.02% | D |
| OCF YoY | -10.65% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 101.26% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Xiangxue Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-10.65%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-55.48%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-14.31",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "6732079584.61",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1525624835.40",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "35.48%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "-10.65%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-55.48%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-10.48%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-106.19%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-11.02%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-10.65%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "101.26%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -4.68 | 168/215 | - | - | - |
| PB | -14.04 | 222/215 | 9.25 | 8.84 | 5.78 |
| PS (TTM) | 4.33 | 117/215 | 4.48 | 4.26 | 3.34 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300147.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300147.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300147.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300147.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**